HRAS
-
Official Full Name
v-Ha-ras Harvey rat sarcoma viral oncogene homolog -
Overview
The 21 kDa guanine-nucleotide binding proteins (K-Ras, H-Ras and N-Ras) cycle between active (GTP-bound) and inactive (GDP-bound) forms. Receptor tyrosine kinases and G-protein-coupled receptors activate Ras, which then stimulates the Raf-MEK-MAPK pathway. GTPase-activating proteins (GAP) normally facilitate the inactivation of Ras. However, in 30% of human tumors, point mutations in Ras prevent the GAP-mediated inhibition of this pathway. The most common oncogenic Ras mutation found in tumors is Gly12 to Asp (G12D), which prevents Ras inactivation, possibly by increasing the overall rigidity of the protein. -
Synonyms
HRAS;v-Ha-ras Harvey rat sarcoma viral oncogene homolog;HRAS1;GTPase HRas;p21ras;H-Ras-1;p19 H-RasIDX protein;c-has/bas p21 protein;transforming protein p21;Ha-Ras1 proto-oncoprotein;c-ras-Ki-2 activated oncogene;GTP- and GDP-binding peptide B;transformation gene: oncogene HAMSV;Ras family small GTP binding protein H-Ras;CTLO;HAMSV;K-RAS;N-RAS;RASH1;C-H-RAS;H-RASIDX;C-BAS/HAS;C-HA-RAS1
Recombinant Proteins
- Human
- Rhesus macaque
- Rat
- Chicken
- Mouse
- Insect Cells
- E.coli
- Mammalian Cell
- Wheat Germ
- Insect Cell
- HEK293
- HEK293T
- Mammalian cells
- In Vitro Cell Free System
- Bacterial
- His
- GST
- Non
- His&Fc&Avi
- Myc&DDK
- Flag
Involved Pathway
HRAS involved in several pathways and played different roles in them. We selected most pathways HRAS participated on our site, such as MAPK signaling pathway,ErbB signaling pathway,Ras signaling pathway, which may be useful for your reference. Also, other proteins which involved in the same pathway with HRAS were listed below. Creative BioMart supplied nearly all the proteins listed, you can search them on our site.
| Pathway Name | Pathway Related Protein |
|---|---|
| Melanoma | KRAS,PDGFC,RAF1,ARAF,IGF1R,FGF3,PIK3CG,FGF6,FGF20,PIK3CA |
| Central carbon metabolism in cancer | PDHA1,PFKM,HKDC1,TRP53,KRAS,PTEN,KIT,RAF1,G6PDX,SLC2A2 |
| Phospholipase D signaling pathway | PLCB3,FCER1A,PDGFB,PDGFRA,RALB,MS4A2,PLD2,MTOR,RHOA,AGPAT3 |
| Fc epsilon RI signaling pathway | TNF,MAP2K7,IL4,SYK,AKT1,PIK3R2,IL5,AKT2,INPP5D,IL13 |
| T cell receptor signaling pathway | GSK3B,NFATC2,CBL,CBLC,IKBKG,CD40LG,NFKBIB,VAV2,MAPK3,DBNLB |
| Prostate Cancer | CCNE1,GRB2,RELA,ERBB2,AKT2,NFKB1,SOS1,NOXA1,HSP90AB1,MAP2K2 |
| PIK-Akt signaling pathway | GNG11,PIK3CD,COL27A1,PDGFB,GNG12,ITGB1,ITGA9,COL6A4,Ifna11,YWHAE |
| Axon guidance | COL6A1,PEA15,UNC5D,EFNA2A,PEA15A,SLIT3,AP2A1,EPHA4,JAK2,DUSP7 |
| Proteoglycans in cancer | PTPN6,FZD1,PRKACB,PLCG2,ERBB2,PTK2,VAV2,RRAS2,PXN,TGFB2 |
Protein Function
HRAS has several biochemical functions, for example, GTP binding,GTPase activity,protein C-terminus binding. Some of the functions are cooperated with other proteins, some of the functions could acted by HRAS itself. We selected most functions HRAS had, and list some proteins which have the same functions with HRAS. You can find most of the proteins on our site.
| Function | Related Protein |
|---|---|
| protein binding | PTPRD,SMARCB1,SFRP4,KRTAP12-1,FKBP8,GMIP,FOXL2,XRCC3,NFKB2,HIST2H4 |
| GTP binding | GBP5,GUCY2E,RHOAB,CDC42L2,SUCLG1,ADSSL,SEPT9,RAB25B,EEFSEC,ARL8B |
| protein C-terminus binding | PPP2CA,PLEKHB1,PABPC1,VGLL2,DLG4,BLOC1S2,C11orf60,PHB2,ERCC1,PHB |
| GTPase activity | RRAGB,RAB6B,SEPT4,ARHGAP5,EIF2S3Y,RAB39B,TUBB6,DDX3X,MX1,RRAD |
Interacting Protein
HRAS has direct interactions with proteins and molecules. Those interactions were detected by several methods such as yeast two hybrid, co-IP, pull-down and so on. We selected proteins and molecules interacted with HRAS here. Most of them are supplied by our site. Hope this information will be useful for your research of HRAS.
RAF1;SOS1
Resources
Related Services
Related Products
References
- South, AP; Purdie, KJ; et al. NOTCH1 Mutations Occur Early during Cutaneous Squamous Cell Carcinogenesis. JOURNAL OF INVESTIGATIVE DERMATOLOGY 134:2630-2638(2014).
- Fukumoto, S; et al. Anti-fibroblast growth factor 23 antibody therapy. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION 23:346-351(2014).
